PFE
Pfizer Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+23/100
Last price
27.50
▲ 0.09 (0.33%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
27.47
Prev close
27.41
Day high
27.71
Day low
27.20
Volume
24.04M
Market cap
$156.74B
P/E (TTM)
36.18
52W range
23.62 – 29.21
Day trading desk
Gap from prior close
+0.22%
Prior close 27.41
VWAP
27.46
+0.16% from price
Relative volume
1.22×
Normal
Session range
2.24%
27.20 – 27.81
Position in range
49%
Mid range
ATR (14D)
0.50
1.81% of price
Prior day high
27.72
PDH
Prior day low
27.12
PDL
Bid / ask spread
—
Quote not published
Session volume
44.49M
Avg 36.36M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.25%
-6.2%
1M
-3.34%
-4.5%
3M
+14.35%
+9.8%
6M
+1.48%
-16.7%
YTD
+10.44%
-3.8%
1Y
+0.47%
-15.9%
3Y
-17.09%
-99.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PFE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+109.58K
Net buying
Buy transactions
3
114.86K shares
Sell transactions
2
5.28K shares
Net transactions
+5
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
5.93M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 12, 26 | BOURLA ALBERT Chief Executive Officer |
BUY | 38.00K | $1.00M | Direct |
| Aug 5, 26 | DAMICO JENNIFER B. Officer |
SELL | 3.28K | $83.26K | Direct |
| Aug 5, 26 | BUCKLEY MORTIMER J. Director |
BUY | 37.63K | $960.37K | Direct |
| Aug 5, 26 | BLAYLOCK RONALD E Director |
BUY | 39.23K | $998.82K | Direct |
| Jun 9, 26 | DAMICO JENNIFER B. Officer |
SELL | 2.00K | $51.40K | Direct |
| Mar 3, 26 | DAMICO JENNIFER B. Officer |
STOCK | 21.72K | $0 | Direct |
| Feb 25, 26 | SAHNI PAYAL Officer |
CONVERSION | 56.89K | $1.92M | Direct |
| Feb 25, 26 | MCDERMOTT MICHAEL Officer |
CONVERSION | 37.92K | $1.28M | Direct |
| Feb 25, 26 | DAMICO JENNIFER B. Officer |
CONVERSION | 17.56K | $593.81K | Direct |
| Feb 25, 26 | BOURLA ALBERT Chief Executive Officer |
CONVERSION | 491.63K | $16.63M | Direct |
| Feb 25, 26 | FONSECA LIDIA PH.D. Officer |
CONVERSION | 56.89K | $1.92M | Direct |
| Feb 25, 26 | LANKLER DOUGLAS M Officer |
CONVERSION | 122.91K | $4.16M | Direct |
| Feb 25, 26 | BOSHOFF CHRISTOFFEL Officer |
STOCK | 13.38K | $0 | Direct |
| Mar 4, 25 | DAMICO JENNIFER B. Officer |
SELL | 2.50K | $64.83K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLAYLOCK RONALD E |
Director | 71.69K | Purchase |
BOSHOFF CHRISTOFFEL |
Officer | 162.09K | Stock Award(Grant) |
BOURLA ALBERT |
Chief Executive Officer | 435.56K | Purchase |
BUCKLEY MORTIMER J. |
Director | 37.63K | Purchase |
DAMICO JENNIFER B. |
Officer | 28.61K | Sale |
FONSECA LIDIA PH.D. |
Officer | 46.45K | Conversion of Exercise of derivative security |
LANKLER DOUGLAS M |
Officer | 165.26K | Conversion of Exercise of derivative security |
MCDERMOTT MICHAEL |
Officer | 74.31K | Conversion of Exercise of derivative security |
SAHNI PAYAL |
Officer | 42.30K | Conversion of Exercise of derivative security |
SUSMAN SALLY |
Officer | 169.78K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$156.74B
Enterprise value$208.82B
Revenue (TTM)$63.70B
Gross profit$47.59B
EBITDA$25.38B
Net income$4.34B
EPS (TTM)$0.76
Free cash flow$12.49B
Total cash$11.70B
Total debt$63.48B
Book value / share$14.95
Shares outstanding5.70B
Float5.69B
Short % of float2.72%
Dividend yield6.28%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E36.18
Forward P/E9.49
PEG ratio12.54
Price / sales—
Price / book1.84
EV / revenue3.28
EV / EBITDA8.23
Gross margin74.72%
Operating margin27.88%
Profit margin6.80%
Return on equity5.01%
Return on assets5.78%
Debt / equity74.25
Current ratio1.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $62.58B | $63.63B | $59.55B | $101.17B | -1.6% |
| Operating revenue | $62.58B | $63.63B | $59.55B | $101.17B | -1.6% |
| Cost of revenue | $16.07B | $17.85B | $24.95B | $34.34B | -10.0% |
| Gross profit | $46.51B | $45.78B | $34.60B | $66.83B | +1.6% |
| Research & development | $10.44B | $10.82B | $10.68B | $11.43B | -3.6% |
| Selling, general & admin | $13.79B | $14.73B | $14.77B | $13.68B | -6.4% |
| Total operating expense | $29.11B | $30.84B | $30.18B | $28.71B | -5.6% |
| Operating income | $17.41B | $14.94B | $4.42B | $38.12B | +16.5% |
| Net interest income | -$2.07B | -$2.55B | -$585.00M | -$987.00M | +18.8% |
| Pre-tax income | $7.52B | $8.02B | $1.06B | $34.73B | -6.3% |
| Tax provision | -$266.00M | -$28.00M | -$1.11B | $3.33B | -850.0% |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | -3.2% |
| Net income to common | $7.77B | $8.03B | $2.12B | $31.37B | -3.2% |
| Basic EPS | 1.37 | 1.42 | 0.38 | 5.59 | -3.5% |
| Diluted EPS | 1.36 | 1.41 | 0.37 | 5.47 | -3.5% |
| EBIT | $10.19B | $11.11B | $3.27B | $35.97B | -8.3% |
| EBITDA | $16.78B | $18.13B | $9.56B | $41.03B | -7.4% |
| Basic shares | 5.68B | 5.66B | 5.64B | 5.61B | +0.3% |
| Diluted shares | 5.71B | 5.70B | 5.71B | 5.73B | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.14B | $1.04B | $2.85B | $416.00M | +9.5% |
| Cash & short-term investments | $13.60B | $20.48B | $12.69B | $22.73B | -33.6% |
| Accounts receivable | $11.87B | $11.46B | $11.57B | $10.95B | +3.6% |
| Inventory | $10.65B | $10.85B | $10.19B | $8.98B | -1.8% |
| Total current assets | $42.90B | $50.36B | $43.33B | $51.26B | -14.8% |
| Property, plant & equipment | $19.32B | $18.39B | $18.94B | $16.27B | +5.0% |
| Goodwill & intangibles | $124.99B | $123.94B | $132.68B | $94.75B | +0.9% |
| Total assets | $208.16B | $213.40B | $226.50B | $197.21B | -2.5% |
| Total current liabilities | $36.98B | $42.99B | $47.79B | $42.14B | -14.0% |
| Current debt | $3.15B | $6.95B | $10.35B | $2.93B | -54.6% |
| Long-term debt | $60.81B | $56.70B | $60.50B | $31.93B | +7.2% |
| Total debt | $63.96B | $63.65B | $70.84B | $34.86B | +0.5% |
| Total liabilities | $121.39B | $124.90B | $137.21B | $101.29B | -2.8% |
| Retained earnings | $114.61B | $116.72B | $118.35B | $125.66B | -1.8% |
| Shareholder equity | $86.48B | $88.20B | $89.01B | $95.66B | -2.0% |
| Working capital | $5.91B | $7.36B | -$4.46B | $9.12B | -19.7% |
| Net tangible assets | -$38.52B | -$35.74B | -$43.67B | $916.00M | -7.8% |
| Shares issued | 9.62B | 9.59B | 9.56B | 9.52B | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $7.79B | $8.05B | $2.17B | $31.40B | — | -3.3% |
| Depreciation & amortisation | $6.59B | $7.01B | $6.29B | $5.06B | — | -6.0% |
| Stock-based compensation | $799.00M | $877.00M | $525.00M | $872.00M | — | -8.9% |
| Change in working capital | -$5.35B | -$3.07B | -$2.17B | -$5.64B | — | -74.6% |
| Operating cash flow | $11.70B | $12.74B | $8.70B | $29.27B | — | -8.2% |
| Capital expenditure | -$2.63B | -$2.91B | -$3.91B | -$3.24B | — | +9.6% |
| Investing cash flow | -$1.35B | $2.65B | -$32.28B | -$15.78B | — | -150.9% |
| Share buybacks | — | $0 | $0 | -$2.00B | $0 | — |
| Dividends paid | -$9.77B | -$9.51B | -$9.25B | -$8.98B | — | -2.7% |
| Financing cash flow | -$10.30B | -$17.14B | $26.07B | -$14.83B | — | +39.9% |
| Free cash flow | $9.07B | $9.84B | $4.79B | $26.03B | — | -7.7% |
| End cash position | $1.20B | $1.11B | $2.92B | $468.00M | — | +8.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | +4.0% |
| Operating revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | +4.0% |
| Cost of revenue | $4.09B | $3.55B | $5.27B | $4.17B | $3.78B | +15.3% |
| Gross profit | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B | +0.4% |
| Research & development | $2.81B | $2.49B | $3.21B | $2.55B | $2.48B | +12.8% |
| Selling, general & admin | $3.41B | $2.96B | $4.16B | $3.19B | $3.42B | +15.2% |
| Total operating expense | $7.41B | $6.63B | $8.60B | $6.96B | $7.11B | +11.6% |
| Operating income | $3.54B | $4.27B | $3.69B | $5.53B | $3.77B | -17.1% |
| Net interest income | -$554.00M | -$553.00M | -$545.00M | -$514.00M | -$498.00M | -0.2% |
| Pre-tax income | -$653.00M | $3.17B | -$1.64B | $3.33B | $3.04B | -120.6% |
| Tax provision | -$407.00M | $461.00M | -$2.00M | -$216.00M | $141.00M | -188.3% |
| Net income | -$248.00M | $2.69B | -$1.65B | $3.54B | $2.91B | -109.2% |
| Net income to common | -$248.00M | $2.69B | -$1.65B | $3.54B | $2.91B | -109.2% |
| Basic EPS | -0.04 | 0.47 | -0.29 | 0.62 | 0.51 | -108.5% |
| Diluted EPS | -0.04 | 0.47 | -0.29 | 0.62 | 0.51 | -108.5% |
| EBIT | $14.00M | $3.84B | -$931.00M | $3.99B | $3.70B | -99.6% |
| EBITDA | $1.64B | $5.45B | $756.00M | $5.65B | $5.32B | -70.0% |
| Basic shares | 5.70B | 5.69B | 5.69B | 5.68B | 5.68B | +0.1% |
| Diluted shares | 5.70B | 5.73B | 5.69B | 5.71B | 5.71B | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $976.00M | $1.70B | $1.14B | $1.34B | $1.64B | -42.7% |
| Cash & short-term investments | $11.70B | $13.07B | $13.60B | $14.98B | $13.25B | -10.5% |
| Accounts receivable | $12.49B | $12.59B | $11.87B | $14.26B | $12.08B | -0.8% |
| Inventory | $9.95B | $10.67B | $10.65B | $11.47B | $11.67B | -6.8% |
| Total current assets | $41.36B | $42.82B | $42.90B | $46.92B | $43.70B | -3.4% |
| Property, plant & equipment | $19.03B | $19.40B | $19.32B | $18.88B | $18.78B | -1.9% |
| Goodwill & intangibles | $118.47B | $123.97B | $124.99B | $120.42B | $121.70B | -4.4% |
| Total assets | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | -3.1% |
| Total current liabilities | $32.65B | $34.35B | $36.98B | $36.60B | $37.73B | -5.0% |
| Current debt | $2.70B | $3.89B | $3.15B | $4.30B | $4.30B | -30.6% |
| Long-term debt | $60.49B | $59.84B | $60.81B | $56.55B | $56.63B | +1.1% |
| Total debt | $63.19B | $63.73B | $63.96B | $60.85B | $60.93B | -0.8% |
| Total liabilities | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | -1.3% |
| Retained earnings | $112.09B | $117.24B | $114.61B | $121.15B | $117.61B | -4.4% |
| Shareholder equity | $85.19B | $90.10B | $86.48B | $92.80B | $88.69B | -5.5% |
| Working capital | $8.71B | $8.47B | $5.91B | $10.33B | $5.98B | +2.8% |
| Net tangible assets | -$33.28B | -$33.87B | -$38.52B | -$27.62B | -$33.01B | +1.7% |
| Shares issued | 5.70B | 9.64B | 9.62B | 9.62B | 9.62B | -40.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$220.00M | $2.68B | -$1.64B | $3.55B | $2.90B | -108.2% |
| Depreciation & amortisation | $1.62B | $1.61B | $1.69B | $1.66B | $1.63B | +0.6% |
| Stock-based compensation | $249.00M | $272.00M | $225.00M | $201.00M | $203.00M | -8.5% |
| Change in working capital | -$1.82B | -$1.73B | $1.59B | -$36.00M | -$4.99B | -4.8% |
| Operating cash flow | $835.00M | $2.62B | $5.35B | $4.60B | -$582.00M | -68.1% |
| Capital expenditure | -$533.00M | -$436.00M | -$845.00M | -$602.00M | -$618.00M | -22.2% |
| Investing cash flow | $2.11B | $785.00M | -$6.15B | -$2.43B | $3.95B | +168.3% |
| Dividends paid | -$2.45B | -$2.44B | -$2.44B | -$2.44B | -$2.44B | -0.2% |
| Financing cash flow | -$3.66B | -$2.86B | $596.00M | -$2.48B | -$3.20B | -28.3% |
| Free cash flow | $302.00M | $2.18B | $4.50B | $4.00B | -$1.20B | -86.1% |
| End cash position | $1.03B | $1.76B | $1.20B | $1.39B | $1.69B | -41.3% |
Options analytics
Put / call volume
0.18
Call-heavy session
Put / call open interest
0.39
Positioning, not flow
Max pain
28.00
+1.8% from spot
ATM implied vol
27.1%
Nearest strike to spot
Skew (10% OTM)
+10.9%
Puts bid over calls
Call volume
8.69K
Contracts, this expiry
Put volume
1.59K
Contracts, this expiry
Heaviest call OI
28.50
20.35K contracts
Heaviest put OI
28.50
5.25K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.68 | 0.77 | +12.9% |
| Mar 2026 | 0.72 | 0.75 | +3.9% |
| Dec 2025 | 0.57 | 0.66 | +16.2% |
| Sep 2025 | 0.63 | 0.87 | +37.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.75 | 18 | $15.91B | -4.5% |
| Next quarter | 0.71 | 18 | $16.93B | -3.6% |
| Current year | 2.97 | 25 | $62.28B | -0.5% |
| Next year | 2.90 | 25 | $59.90B | -3.8% |
Analyst targets & ownership
Mean target$28.91
High target$35.75
Low target$25.00
Implied upside5.14%
Analyst count26
ConsensusBUY
Strong buy / Buy2 / 8
Hold16
Sell / Strong sell1 / 1
Held by insiders0.10%
Held by institutions69.12%
Institutions holding3.62K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
28.20
-2.50% from price
SMA 20
27.94
-1.59% from price
SMA 50
27.44
+0.21% from price
SMA 100
26.28
+4.64% from price
SMA 200
26.42
+4.08% from price
EMA 12
27.98
-1.72% from price
EMA 26
27.88
-1.37% from price
EMA 50
27.44
+0.23% from price
RSI (14)
43.6
Neutral
MACD (12,26,9)
0.10
Hist -0.13
ATR (14)
0.50
1.81% of price
Realised vol 30D
15.8%
Annualised
Bollinger upper
28.80
20, 2σ
Bollinger lower
27.09
20, 2σ
50 / 200 cross
Golden
27.44 vs 26.42
Trend bias
Above 200
+4.08%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.30
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
15.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-17.1%
Peak to trough
Max drawdown 5Y
-64.8%
Peak to trough
ATR 14
0.50
1.81% of price
Beta (reported)
0.28
5Y monthly, from filing
Short interest
Shares short
155.20M
Prior 149.27M
Change vs prior
+4.0%
Shorts adding
% of float
2.72%
Normal
% of shares out
2.72%
Against total outstanding
Days to cover
4.6
Liquid
Float
5.69B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Scotiabank | MAINTAINED | Sector Outperform | Sector Outperform |
| Sep 10, 26 | HSBC | MAINTAINED | Hold | Hold |
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 13, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Jul 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 10, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Jul 8, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Jul 6, 26 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
| Jul 6, 26 | HSBC | DOWNGRADE | Buy | Hold |
| Jun 10, 26 | RBC Capital | UPGRADE | Underperform | Sector Perform |
| Apr 29, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Apr 20, 26 | RBC Capital | MAINTAINED | Underperform | Underperform |
Dividends & splits
Forward rate$1.72 / yr
Forward yield6.28%
5-year avg yield4.76%
Payout ratio226.32%
Ex-dividend dateJul 24, 2026
Next pay dateSep 1, 2026
Last split1054:1000
Split dateNov 17, 2020
SEC filings
Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
N-PX · 2026-08-31
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-18
Annual report of employee stock purchase
11-K · 2026-06-16
Offering Registrations
S-8 · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-04-27
Annual Report to Shareholders
ARS · 2026-03-12
Periodic Financial Reports
10-K · 2026-02-26
Headlines
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
PR Newswire · 2h ago
Novavax, Moderna stocks fall after WHO calls plague risk 'low'
Yahoo Finance · 4h ago
Is Pfizer (PFE) a Good or Bad Investment at Today’s Price?
Insider Monkey · 5h ago
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
24/7 Wall St. · 6h ago
Pfizer Keeps Its Dividend Steady With a Yield Above 6%
GuruFocus.com · 7h ago
3 of the Best Dividend Stocks to Buy in October 2026
Motley Fool · 8h ago
Scotiabank Adjusts Pfizer Price Target to $33 From $30, Sector Outperform Rating Kept
MT Newswires · 9h ago
PFE vs. JNJ: Which Stock Is the Better Value Option?
Zacks · 10h ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.